Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer

Breast

Volumn 22, Issue 1, 2013, Pages 58-63

  Blasinska Morawiec, Maria ^a   Tubiana Mathieu, Nicole ^b   Fougeray, Ronan ^c   Pinel, Marie Claire ^c   Bougnoux, Philippe ^d  

^a M Kopernik Hospital   (Poland)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d CHU BRETONNEAU   (France)

Author keywords

Advanced breast cancer; Phase II; Single agent; Vinflunine

Indexed keywords

NAVELBINE; VINFLUNINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; JAW PAIN; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 84871718734     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.10.007     Document Type: Article

References (25)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Cancer global statistics. CA Cancer J Clin 2011, 61:69-90.
2. National comprehensive cancer network NCCN clinical practices guidelines in oncology. V2 2011, http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
3. Blum J., Dieras V., Lorusso P., et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2000, 92:1759-1768.
4. Blum J., Jones S., Buzdar A., et al. Multicenter, phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999, 17:485-493.
5. Jones S., Winer E., Vogel C., et al. Randomised comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995, 13:2567-2574.
6. Zeleck L., Barthier S., Riofria M., et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001, 92:2267-2272.
7. Martin M., Ruiz A., Munoz M., et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007, 8:219-225.
8. Thomas E., Tabernero J., Fornier M., et al. Phase II clinical trial of ixabepilone, an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399-3406.
9. Cortes J., O'Shaughnessy J., Loesch D., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase III open-label, randomised study. Lancet 2011, 377:914-923.
10. Jacquesy J.C., Fabry I. Superacidic generation of new antitumour agents. Biomedical chemistry: applying chemical principles to the understanding and treatment of disease 2000, 227-245. John Wiley & Sons, New York, NY. P. Torrens (Ed.).
11. Hill B.T. Vinflunine, a second generation novel vinca-alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr Pharm Des 2001, 7:1199-1212.
12. Etievant C., Barret J.M., Kruczynski A. Vinflunine (20_,20_-difluoro-3_,4_-dihydrovinorelbine), a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)- mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998, 16:3-17.
13. Ngan V.K., Bellman K., Hill B.T., et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001, 60:225-232.
14. Jean-Decoster C., Brichese L., Barret J.M., et al. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anticancer Drugs July 1999, 10(6):537-543.
15. Lobert S., Ingram J.W., Hill B.T., et al. A comparison of thermodynamic parameters for vinorelbine and vinflunine induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998, 53:908-915.
16. Aggarwal A., Kruczinski A., Frankfurter A., et al. Murine leukemia 2388 vinorelbine-resistant cell lines are sensitive to vinflunine. Invest New Drugs 2008, 26:319-330.
17. Schutz F., Bellmunt J., Rosenberg J., et al. Vinflunine: drug safety evaluation of this novel synthetic vinca-alkaloid. Expert Opin Drug Saf 2011, 10:645-653.
18. Culine S., Theodore C., De Santis M., et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006, 94:1395-1401.
19. Bellmunt J., Theodore C., Demkov T., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009, 27:4454-4461.
20. Campone M., Cortes-Funes, Vorobiof D., Martin M., Slabber C.F., Ciruelos E., et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 2006, 95:1161-1166.
21. Fumoleau P., Cortes-Funes H., Taleb A., Chan S., Campone M., Pouget J.C., et al. Phase II study of single-agent iv vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline/taxane-based chemotherapy. Am J Clin Oncol 2009, 32(4):375-380.
22. Therasse P., Arbruck S.G., Eisenhauer E., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 Feb 2, 92(3):205-216.
23. Fleming T.R. One sample multitesting. Procedure for phase II clinical trials. Biometrics 1982, 38:143-145.
24. Shuster J.J. Median follow-up in clinical trials. J Clin Oncol 1991, 9:191-192.
25. Amit O., Mannino F., Stone A.M., Bushnell W., Denne J., Helterbrand J., et al. Blinded independent central review of progression in cancer clinical trials: results from a meta analysis. Eur J Cancer 2011, 47:1772-1778.